The DOI matches its Crossref record; 49 of the 52 references it cites were found in a registry or an index.
Anticancer Drug Conjugates Incorporating Estrogen Receptor Ligands
Open accessAbstract
Hormone-dependent cancers, such as certain types of breast cancer are characterized by over-expression of estrogen receptors (ERs). Anticancer drug conjugates combining ER ligands with other classes of anticancer agents may not only benefit from dual action at both anti-cancer targets but also from selective delivery of cytotoxic agents to ER-positive tumor cells resulting in less toxicity and adverse effects. Moreover, they could also take advantage of overcoming resistance typical for anti-hormonal monotherapy such as tamoxifen. In this review, we discuss the design, structures and pharmacological effects of numerous series of drug conjugates containing ER ligands such as selective ER modulators (tamoxifen, 4-hydroxytamoxifen, endoxifen), selective ER degraders (ICI-164384) and ER agonists (estradiol) linked to diverse anti-cancer agents including histone-deacetylase inhibitors, DNA-alkylating agents, antimitotic agents and epidermal growth factor receptor inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The released 4-OH-TAM exerts a direct anti-estrogenic effect, thereby mitigating the unsatisfactory therapeutic outcomes associated with the differences in TAM metabolism.”
From Multifunctional and dual-targeting polymeric prodrug nanomicelles against tamoxifen-resistant breast cancer (2026) · cites this paper as [21]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Overexpression of epidermal growth factor receptor (EGFR), variations in TAM metabolism, and increased expression of drug-resistant proteins (P-glycoprotein, P-gp) all contribute to the development of TAM-resistant breast cancer.”
From Multifunctional and dual-targeting polymeric prodrug nanomicelles against tamoxifen-resistant breast cancer (2026) · cites this paper as [21]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21590 · Cited by 20,444 · cited 1×
“Breast cancer is the most common type of neoplasia among women [11].”
BackgroundLipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Molecular properties that influence the oral bioavailability of drug candidates
Veber, D. F., Johnson, S. R., Cheng, H.-Y., Smith, B. R., Ward, K. W., & Kopple, K. D. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020017n · Cited by 8,420 · cited 1×
“Especially the hybrid ligands with the pharmacophores connected by longer spacers are large chemical entities with molecular mass exceeding 500 Da and often high lipophilicity and violate Lipinski’s [47] and Veber’s [48] rules that assess molecular properties influencing oral bioavailability.”
BackgroundDesigned Multiple Ligands. An Emerging Drug Discovery Paradigm
Morphy, R., & Rankovic, Z. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm058225d · Cited by 1,209 · cited 1×
“A challenge for the design and development of drug conjugates as anticancer therapeutics is the optimization of their physicochemical properties towards a favorable pharmacokinetic profile [46].”
BackgroundJin, Y., Desta, Z., Stearns, V., Ward, B., Ho, H., Lee, K.-H., Skaar, T., Storniolo, A. M., Li, L., Araba, A., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji005 · Cited by 951 · cited 2×
“Structures of major metabolites of tamoxifen, their plasma concentrations in women taking tamoxifen [36], their antagonist activities at ERα [29] and binding affinities to rat uterine ERs [37].”
BackgroundAntibody-drug conjugates: recent advances in conjugation and linker chemistries
Tsuchikama, K., & An, Z. (2018) · Protein & Cell · doi:10.1007/s13238-016-0323-0 · Cited by 786 · cited 1×
“While ADCs have been successfully introduced as cancer therapeutics [5], hybrid anticancer agents have mostly been reported in preclinical studies [4].”
BackgroundMechanisms of tamoxifen resistance
Ring, A., & Dowsett, M. (2004) · Endocrine-Related Cancer · doi:10.1677/erc.1.00776 · Cited by 651 · cited 1×
“However, its chronic use can increase the risk of uterine cancer [20] and induce tamoxifen resistance [21].”
BackgroundWijayaratne, A. L., & McDonnell, D. P. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101097200 · Cited by 427 · cited 1×
“Moreover, SERDs are known to induce ubiquitination and degradation of ERα through the proteasome pathway [16].”
BackgroundUpdate on melatonin receptors: IUPHAR Review 20
Jockers, R., Delagrange, P., Dubocovich, M. L., Markus, R. P., Renault, N., Tosini, G., Cecon, E., & Zlotos, D. P. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13536 · Cited by 422 · cited 1×
“The higher MT1-affinity of compound 3 compared to the parent drug is rather surprising taking into account that according to the well-established SARs, alkyl substituents larger than propyl attached to the amide carbonyl group of melatonin reduce binding affinity to melatonin receptors [33,34].”
BackgroundSelf-citation
Research works printed but not linked: 2
- (2022, December 22). Available online: https://pubmed.ncbi.nlm.nih.gov/?term=anticancer+hybrids.
- (2022, December 22). Available online: https://adisinsight.springer.com/drugs/800028795.
Cited by
PROTACs: A novel strategy for cancer drug discovery and development
Han, X., & Sun, Y. N. (2023) · MedComm · doi:10.1002/mco2.290 · Cited by 77
Martino, S. D., & Rosa, M. D. (2024) · Topics in Current Chemistry · doi:10.1007/s41061-024-00477-6 · Cited by 39
Galvani, F., Cammarota, M., Vacondio, F., Rivara, S., & Boscia, F. (2024) · Journal of Pineal Research · doi:10.1111/jpi.70008 · Cited by 25
Wang, L., Guo, X., Qin, J., Jin, Z., Liu, Q., Sun, C., Sun, K., Li, L., Wei, X., & Zhang, Y. (2024) · Osteoporosis International · doi:10.1007/s00198-024-07225-y · Cited by 8
Ryzhikova, O. V., Churkina, A. S., Sedenkova, K. N., Savchenkova, D. V., Shakhov, A. S., Lavrushkina, S. V., Grishin, Y. K., Зефиров, Н. А., Zefirova, O. N., Gracheva, Y. A., et al. (2024) · Archiv der Pharmazie · doi:10.1002/ardp.202400483 · Cited by 3
Metadata
- Authors
- Zlotos, D. P., Kronenberger, T., & Laufer, S. A.
- Affiliations
- German University in Cairo (EG)
- Universitätsklinikum Tübingen (DE)
- University of Tübingen (DE)
- Corresponding author
- Zlotos, Darius P.
- Laufer, Stefan A.
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2022-12-26
- Volume
- 15
- Issue
- 1
- Pages
- 67
- ISSN
- 1999-4923 (ISSN-L)
- PMC
- PMC9866829
- OpenAlex
- W4313245134
- Cited by
- 9
- References
- 52
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 5 · 2023: 1
- FWCI
- 0.31
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceutics (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- German Academic Exchange Service (Sustainable Research Cooperation between GUC and Tuebingen University)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- estrogen receptor ligands, hormone-dependent breast cancer, tamoxifen, endoxifen, 4-hydroxytamoxifen, selective estrogen receptor modulators, selective estrogen receptor degrader, estradiol, histone deacetylase inhibitors, DNA alkylating agents, antimitotic agents, EGFR inhibitors, targeted drug delivery, tamoxifen resistance
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anticancer Drug Conjugates Incorporating Estrogen Receptor Ligands. https://app.cochat.ai/papers/10.3390/pharmaceutics15010067
- The paper
- Zlotos, D. P., Kronenberger, T., & Laufer, S. A. (2022). Anticancer Drug Conjugates Incorporating Estrogen Receptor Ligands. Pharmaceutics. https://doi.org/10.3390/pharmaceutics15010067
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.